Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

G

Grady BJ, Torstenson ES, McLaren PJ, et al. "Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants." Pac Symp Biocomput. 2011:253-64.
Graham CS, Wells A, Liu T, et al. "Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection." AIDS. 2006;20(3):345-51.
Grant PM, Komarow L, Lederman MM, et al. "Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164." J. Infect. Dis.. 2012;206(11):1715-23.
Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT. "Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults." HIV Clin Trials. 2015;16(2):66-71.
Grant PM, Kitch D, McComsey GA, et al. "Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals." J. Infect. Dis.. 2016;214(4):607-11.
Grant PM, Kitch D, McComsey GA, et al. "Long-term body composition changes in antiretroviral-treated HIV-infected individuals." AIDS. 2016;30(18):2805-2813.
Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Grant PM, Tierney C, Budhathoki C, et al. "Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202." HIV Clin Trials. 2013;14(6):284-91.
Grant PM, Kitch D, McComsey GA, et al. "Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation." Clin. Infect. Dis.. 2013;57(10):1483-8.
Grant PM, Komarow L, Andersen J, et al. "Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection." PLoS ONE. 2010;5(7):e11416.
Greer AE, San Ou S-, Wilson E, et al. "Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052." J. Acquir. Immune Defic. Syndr.. 2017;76(4):388-393.
Grinsztejn B, Smeaton L, Barnett R, et al. "Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count." Antivir. Ther. (Lond.). 2011;16(7):1057-62.
Gripshover BM, Ribaudo H, Santana J, et al. "Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)." Antivir. Ther. (Lond.). 2006;11(5):619-23.
Gross R, Tierney C, Andrade A, et al. "Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial." Arch. Intern. Med.. 2009;169(13):1224-32.
Gross R, Zheng L, La Rosa A, et al. "Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234)." Lancet HIV. 2015;2(1):e12-e19.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial." Ann. Intern. Med.. 2017;167(6):384-393.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Gulick RM, Su Z, Flexner C, et al. "Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211." J. Infect. Dis.. 2007;196(2):304-12.
Gupta SK, Kitch D, Tierney C, Melbourne K, Ha B, McComsey GA. "Markers of renal disease and function are associated with systemic inflammation in HIV infection." HIV Med.. 2015;16(10):591-8.
Gupta SK, Yeh E, Kitch DW, et al. "Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s." J. Antimicrob. Chemother.. 2017;72(7):2042-2048.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szczech LA, Kalayjian RC. "The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era." Antivir. Ther. (Lond.). 2009;14(4):543-9.
Gupta SK, Rosenkranz SL, Cramer YS, et al. "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis." AIDS. 2008;22(15):1919-27.
Gupta SK, Komarow L, Gulick RM, et al. "Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects." J. Infect. Dis.. 2009;200(4):614-8.
Gupta SK, Kitch D, Tierney C, et al. "Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial." Open Forum Infect Dis. 2014;1(1):ofu003.

Pages